Last week, the Office of National AIDS Policy (ONAP) convened the National HIV/AIDS Strategy Federal Implementation Workgroup (NHAS FIW) to launch the process to begin development of the NHAS Federal Implementation Plan (NHAS FIP).
On December 20th, the U.S. Food and Drug Administration (FDA) announced its first approval of a long-acting HIV prevention medication. Developed by ViiV Healthcare, the medicine is long-acting cabotegravir injected once every two months.
The new National HIV/AIDS Strategy 2022-2025 was released in December 9, 2021.
"After more than 30 years of HIV research and significant biomedical advancements to treat and prevent HIV, most HIV criminalization laws do not reflect current scientific and medical evidence."
The December 2021 update of CDC PrEP guidelines contains a series of recommendations for providers to broaden their discussions and prescribing of the HIV preventive regimen.
The New Jersey Department of Health released a plan proposed by the New Jersey Taskforce to End the HIV Epidemic entitled, “A Strategic Plan to End the HIV Epidemic in New Jersey by 2025.”
La Oficina de VIH / SIDA (HAB) de la Administración de Recursos y Servicios de Salud (HRSA) publicó el Aviso de Política (PN) 21-02, que reemplaza la Política Número 13-07, vigente a partir del 1 de octubre de 2021.
La Oficina de VIH / SIDA (HAB) de la Administración de Recursos y Servicios de Salud (HRSA) publicó el Aviso de aclaración de políticas (PCN) 21-02, el 19 de octubre de 2021.
Acting Attorney General Andrew J. Bruck provides factors to consider as guidance behind whether to criminally charge individuals under N.J.S.A. 2C:34-5(b) in light of advancements in treatment for HIV/AIDS.